BrokeInvest
2021-08-13

$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong execution

to ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法